GlassScriptPhysician profile
Shital Tanna
NPI 1578561767
$3,006.41
in general payments reported to CMS, 2019-2025
14 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $377 · 2021: $476 · 2022: $511 · 2023: $595 · 2024: $368 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.92 |
| Education | $193.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,812.29 | 2019-2025 | Ozempic |
| Glaxosmithkline, LLC. | $242.44 | 2023 | Shingrix, Arexvy, Bexsero |
| Nxstage Medical, INC. | $186.64 | 2022-2023 | Nxstage System One, Liberty Select Cycler |
| Medtronic, INC. | $123.20 | 2021-2022 | |
| Boston Scientific Corporation | $106.31 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $105.37 | 2020 | |
| Janssen Pharmaceuticals, INC | $100.67 | 2019-2022 | |
| Amgen INC. | $95.46 | 2021 | |
| Covidien LP | $70.67 | 2019 | |
| Lilly USA, LLC | $57.67 | 2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $47.82 | 2019 | |
| Dexcom, INC. | $24.96 | 2021 | |
| Merck Sharp & Dohme LLC | $17.24 | 2019 | |
| Pfizer INC. | $15.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shital Tanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.